Patients with asthma should use intermediate-acting inhaled β 2 -agonists only on an as-needed basis

Author： Adis International Limited  

Publisher： Adis International

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.22, Iss.1, 2006-01, pp. : 12-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of combination long-acting β-2 agonists and inhaled glucocorticosteroids for treatment of asthma

By Kim Dennis   Glaum Mark   Lockey Richard  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 8, 2009-08 ,pp. : 933-940

Informa Healthcare

Access to resources Recommend Favorite

Inhaled corticosteroids plus long-acting &bgr;2-agonists as a combined therapy in asthma

By García-Marcos Luis   Schuster Antje   Barroso Nicolás Cobos  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 1, 2003-01 ,pp. : 23-39

Informa Healthcare

Access to resources Recommend Favorite

Advances in Asthma and COPD Treatment: Combination Therapy with Inhaled Corticosteroids and Long-Acting &bgr;2-Agonists.

By  

Current Pharmaceutical Design, Vol. 12, Iss. 25, 2006-01 ,pp. : 3261-3279

Bentham Science Publishers

Access to resources Recommend Favorite

Long-acting β2 agonists

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 1, 2006-01 ,pp. : 99-104

Informa Healthcare

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Inhaled Long-Acting β 2 -Agonists in the Management of Obstructive Pulmonary Disease

By Sovani Milind P.   Whale Christopher I.   Tattersfield Anne. E.  

Drug Safety, Vol. 27, Iss. 10, 2004-01 ,pp. : 689-715

Adis International

Access to resources Recommend Favorite